[go: up one dir, main page]

ZA200203313B - Oral solution containing galanthamine and a sweetening agent. - Google Patents

Oral solution containing galanthamine and a sweetening agent.

Info

Publication number
ZA200203313B
ZA200203313B ZA200203313A ZA200203313A ZA200203313B ZA 200203313 B ZA200203313 B ZA 200203313B ZA 200203313 A ZA200203313 A ZA 200203313A ZA 200203313 A ZA200203313 A ZA 200203313A ZA 200203313 B ZA200203313 B ZA 200203313B
Authority
ZA
South Africa
Prior art keywords
solution containing
sweetening agent
oral solution
containing galanthamine
galanthamine
Prior art date
Application number
ZA200203313A
Other languages
English (en)
Inventor
Marc Karel Josef Francois
Eddy Andre Josee De Proost
Tony Mathilde Jozef Kempen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200203313B publication Critical patent/ZA200203313B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ZA200203313A 1999-10-26 2002-04-25 Oral solution containing galanthamine and a sweetening agent. ZA200203313B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203512 1999-10-26

Publications (1)

Publication Number Publication Date
ZA200203313B true ZA200203313B (en) 2003-11-26

Family

ID=8240778

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203313A ZA200203313B (en) 1999-10-26 2002-04-25 Oral solution containing galanthamine and a sweetening agent.

Country Status (29)

Country Link
EP (1) EP1237539B1 (is)
JP (1) JP2003512415A (is)
KR (1) KR100502391B1 (is)
CN (1) CN1200691C (is)
AR (1) AR026243A1 (is)
AT (1) ATE306904T1 (is)
AU (1) AU780826C (is)
BG (1) BG65792B1 (is)
BR (1) BR0015025A (is)
CA (1) CA2388830C (is)
CZ (1) CZ301996B6 (is)
DE (1) DE60023341T2 (is)
DK (1) DK1237539T3 (is)
EA (1) EA005683B1 (is)
EE (1) EE05230B1 (is)
ES (1) ES2250211T3 (is)
HR (1) HRP20020332B1 (is)
HU (1) HUP0203484A3 (is)
IL (2) IL149310A0 (is)
IS (1) IS2628B (is)
MX (1) MXPA02004149A (is)
NO (1) NO332096B1 (is)
PL (1) PL201694B1 (is)
SI (1) SI1237539T1 (is)
SK (1) SK285643B6 (is)
TW (1) TW592725B (is)
UA (1) UA76095C2 (is)
WO (1) WO2001030318A1 (is)
ZA (1) ZA200203313B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
CA2535613A1 (en) 2003-08-13 2005-02-24 Janssen Pharmaceutica, N.V. Treatment of sleep disorders with cholinesterase inhibitors
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US8709521B2 (en) * 2007-05-22 2014-04-29 The Coca-Cola Company Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles
BR112013018898B1 (pt) * 2011-01-27 2021-10-05 Neuren Pharmaceuticals Limited Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
JP6457582B2 (ja) * 2017-04-14 2019-01-23 エルメッド エーザイ株式会社 ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤
CN117717558A (zh) * 2023-12-06 2024-03-19 艾威药业(珠海)有限公司 加兰他敏及其药学上可接受的盐在制备治疗眼部疾病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
JPH10273435A (ja) * 1997-01-29 1998-10-13 Fujisawa Pharmaceut Co Ltd 内服用液剤

Also Published As

Publication number Publication date
HRP20020332B1 (hr) 2011-02-28
MXPA02004149A (es) 2002-10-17
NO332096B1 (no) 2012-06-18
EA005683B1 (ru) 2005-04-28
CZ301996B6 (cs) 2010-09-01
HUP0203484A3 (en) 2004-12-28
EE05230B1 (et) 2009-12-15
HK1049619A1 (en) 2003-05-23
EP1237539B1 (en) 2005-10-19
CA2388830C (en) 2006-09-19
SI1237539T1 (sl) 2006-04-30
ES2250211T3 (es) 2006-04-16
KR20020026010A (ko) 2002-04-04
BR0015025A (pt) 2002-06-18
WO2001030318A1 (en) 2001-05-03
AU780826C (en) 2006-02-16
ATE306904T1 (de) 2005-11-15
EP1237539A1 (en) 2002-09-11
EA200200486A1 (ru) 2002-10-31
DE60023341T2 (de) 2006-07-27
CZ20021329A3 (cs) 2002-08-14
IS2628B (is) 2010-05-15
PL362849A1 (en) 2004-11-02
KR100502391B1 (ko) 2005-07-19
NO20022003D0 (no) 2002-04-26
DK1237539T3 (da) 2006-02-27
PL201694B1 (pl) 2009-04-30
JP2003512415A (ja) 2003-04-02
BG106534A (en) 2002-12-29
TW592725B (en) 2004-06-21
IL149310A0 (en) 2002-11-10
AR026243A1 (es) 2003-02-05
AU780826B2 (en) 2005-04-21
HUP0203484A2 (hu) 2003-02-28
CA2388830A1 (en) 2001-05-03
SK285643B6 (sk) 2007-05-03
SK5302002A3 (en) 2002-10-08
UA76095C2 (en) 2006-07-17
CN1382037A (zh) 2002-11-27
IL149310A (en) 2006-12-10
NO20022003L (no) 2002-06-18
IS6291A (is) 2002-02-28
CN1200691C (zh) 2005-05-11
DE60023341D1 (de) 2006-03-02
EE200200213A (et) 2003-06-16
HRP20020332A2 (en) 2004-02-29
BG65792B1 (bg) 2009-12-31
AU1384901A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
AU141207S (en) A capsule
PL346530A1 (en) Azetidine derivatives, preparation and medicines containing them
ZA200202480B (en) Oral dosage forms.
HUP0203204A3 (en) Oral dosage forms
IL141769A0 (en) Azetidine derivatives, preparation and medicines containing them
PL342515A1 (en) Drug administering device
EP1145714A4 (en) DRUGS
ZA200203313B (en) Oral solution containing galanthamine and a sweetening agent.
HUP0100939A3 (en) Spiropiperidine derivatives, medicaments containing them and their use
GB2334805B (en) Oxygen dispenser
EP1201245A4 (en) FUNCTIONAL ORAL PREPARATIONS
EP1091783A4 (en) DISTRIBUTOR OF DRUGS
GB9817613D0 (en) Time capsule
GB9828620D0 (en) Medicaments
AU139311S (en) Floss container
GB9827865D0 (en) Medicament
IL126732A0 (en) Pro drug
GB9904935D0 (en) Medicaments
GB9915111D0 (en) Millennium Time Capsule
GB9803615D0 (en) Gum spittoon
GB9810377D0 (en) Dose reminder device
GB9809797D0 (en) Time capsule
GB9827285D0 (en) Medicament
GB9817943D0 (en) Genostics and drugs
TW406571U (en) Mouth mask